Who owns Allogene Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ALLO from SEC Form 13F filings across 197 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 197 institutions disclosed 303.8M shares of Allogene Therapeutics, Inc. worth $487.1M — about 87.8% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
197
13F holders
$487.1M
value, 2026 filers
87.8%
of shares outstanding (303.8M sh)
25
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ALLO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 30.9M | $49.5M | 0.0% | 8.9% | +2.6% |
| 2 | CITADEL ADVISORS LLC | 24.6M | $39.3M | 0.0% | 7.1% | +143.4% |
| 3 | Frazier Life Sciences Management, L.P. | 22.4M | $35.9M | 0.9% | 6.5% | 0.0% |
| 4 | Pfizer Inc | 22.0M | $36.4M | 22.1% | 6.4% | 0.0% |
| 5 | STATE STREET CORP | 16.3M | $26.1M | 0.0% | 4.7% | -14.2% |
| 6 | PRIMECAP MANAGEMENT CO/CA/ | 13.1M | $21.0M | 0.0% | 3.8% | +0.2% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 12.1M | $19.3M | 0.0% | 3.5% | -1.0% |
| 8 | UBS Group AG | 10.7M | $17.1M | 0.0% | 3.1% | +252.3% |
| 9 | FMR LLC | 10.6M | $17.0M | 0.0% | 3.1% | -11.7% |
| 10 | Sio Capital Management, LLC | 9.1M | $14.6M | 2.8% | 2.6% | -31.7% |
| 11 | TWO SIGMA INVESTMENTS, LP | 9.0M | $14.4M | 0.0% | 2.6% | +15.8% |
| 12 | MARSHALL WACE, LLP | 8.0M | $12.8M | 0.0% | 2.3% | +56.5% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 6.4M | $10.3M | 0.0% | 1.9% | -8.5% |
| 14 | Candriam S.C.A. | 5.4M | $8.7M | 0.0% | 1.6% | +25.1% |
| 15 | GOLDMAN SACHS GROUP INC | 5.3M | $8.5M | 0.0% | 1.5% | -13.3% |
| 16 | GordonMD Global Investments LP | 5.3M | $8.5M | 5.1% | 1.5% | 0.0% |
| 17 | Aberdeen Group plc | 5.3M | $8.4M | 0.0% | 1.5% | +5.2% |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 5.2M | $8.4M | 0.0% | 1.5% | +36.5% |
| 19 | MILLENNIUM MANAGEMENT LLC | 5.1M | $8.2M | 0.0% | 1.5% | +5.6% |
| 20 | Patient Square Capital LP | 4.5M | $7.3M | 1.2% | 1.3% | -9.9% |
| 21 | D. E. Shaw & Co., Inc. | 4.3M | $6.8M | 0.0% | 1.2% | -9.5% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9M | $6.2M | 0.0% | 1.1% | -8.3% |
| 23 | HRT FINANCIAL LP | 3.3M | $5.4M | 0.0% | 1% | -7.6% |
| 24 | MORGAN STANLEY | 3.3M | $5.3M | 0.0% | 1% | -26.2% |
| 25 | RTW INVESTMENTS, LP | 3.3M | $5.2M | 0.1% | 0.9% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.